Section Arrow
DNTH.NASDAQ
- Dianthus Therapeutics
Quotes are at least 15-min delayed:2025/06/02 00:16 EDT
Last
 17.37
-0.48 (-2.69%)
Day High 
18.3 
Prev. Close
17.85 
1-M High
22.14 
Volume 
238.84K 
Bid
7.06
Ask
21.42
Day Low
16.91 
Open
17.6 
1-M Low
17.4 
Market Cap 
574.06M 
Currency USD 
P/E 3.03 
%Yield -- 
10-SMA 18.58 
20-SMA 19.44 
50-SMA 19.18 
52-W High 32.27 
52-W Low 13.365 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.83/-4.17
Enterprise Value
575.23M
Balance Sheet
Book Value Per Share
10.22
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
6.24M
Operating Revenue Per Share
0.20
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
INABIN8bio0.1446-0.0088-5.74%-- 
BLRXBioLineRx Ltd5.18+1.3891+36.64%-- 
IMNNImunon2.45+0.46+23.12%-- 
NCNANuCana plc0.03525-0.00175-4.73%-- 
MRNAModerna26.58-0.35-1.30%-- 
Quotes are at least 15-min delayed:2025/06/02 00:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.